AllDocs -> cancers

Page 2 Current Status of Management of Adult Non-Hodgkin’s Lymphoma in Egypt By Dr. Hussein M. Khaled Professor of Medical Oncology Dean , National Cancer Institute Cairo University Page 3 Page 4 Adapted from Greenlee RT, et al. CA Cancer J Clin. 2000;51:18, 15-36. stimated deaths stimated deaths Estimated incidence E Estimated incidence E Melanoma of skin Oral cavity & pharynx Lung & bronchus Pancreas Kidney Colon & rectum Prostate Urinary bladder Leukemia Non-Hodgkin’s lymphoma All others 5% 3% 14% 2% 3% 10% 31% 6% 3% 5% 18% Esophagus Lung & bronchus Pancreas Liver Kidney ...

BCCA Protocol Summary for Treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis Protocol Code ULYMFECP Tumour Group Lymphoma Contact Physician Dr. Nicholas Voss ELIGIBILITY : Special: Only patients with advanced, progressive, refractory cutaneous T-cell lymphoma (erythroderma or stages T2/3 with circulating Sézary cells) who have failed at least two prior systemic chemotherapy agents, not including retinoids, and have failed or are unable to tolerate Bexarotene should be considered for ECP. This means that they have either failed to respond to or have relapsed after these treatments. Histology: mycosis fungoides or Sézary syndrome Adequate immune system with near normal WBC (excluding Sézary cells) Normal/near normal CD8 count An “Undesignated Indications Request Form” must be approved. EXCLUSIONS ...

NH LYMPHOMA BOTH SEXES TABLE 1A. -- Characteristics of persons reported to the Connecticut Tumor Registry with an initial non-Hodgkin's lymphoma , 1935-82+ _ Category Male Female Total _ No. with first primary cancer* 3,539 3,195 6,734 No. who developed a second primary cancer 196 123 319 Average age at diagnosis of first cancer, yr 56 60 58 Average yr of diagnosis of first cancer 1966 1967 1967 Person-yr of follow-up 14,378 12,854 27,231 Average follow-up, yr 4.1 4.0 4.0 Percent given radiotherapy for first cancer 52.0 50.5 51.3 _ + ICD-O morphology codes = 9590-9642,9690-9701,9750. * Number excludes all persons who survived less than 2 mo after the diagnosis of their first primary cancer or who developed a simultaneous cancer during this period. First primary cancers diagnosed only at autopsy or by death certificate are also excluded as are in situ cancers. TABLE 1B. -- Microscopic ...

Lymphoma Lymphoma is a general term for a cancer that begins in the lymphatic system. There are two main types of lymphoma : non-Hodgkin lymphoma and Hodgkin lymphoma . Non-Hodgkin lymphoma is one of the most common cancers in Victoria, affecting over 1000 people a year. It can occur in children but is more common in adults. Hodgkin lymphoma is much less common. About 120 Victorians are affected each year. The lymphatic system The lymphatic system is part of the immune system, which defends the body against infection. It consists of lymph nodes connected by lymph vessels, which branch out into all parts of the body except the brain and spinal cord. The lymphatic system also includes the bone marrow, spleen, thymus gland, tonsils, adenoids and appendix. Lymph is the fluid that flows through the lymph vessels. It contains white blood cells called ...

For research use only A224 - Lymphoma (formalin fixed) Specifications: • No. of cases: 48 • Tissue type: Lymphoma • No. of spots: 2 spots from each cancer case (96 spots) 8 non-neoplastic spots (8 spots) •Total spots: 104 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 Summary of tissue spots For research use only (formalin fixed) No Sex Age Keyword Stage 1 A 1,2 m 35 Lymph node: Hodgkin's disease ?B 2 A 3,4 f 39 Lymph node: Hodgkin's disease ?A 3 A 5,6 m 46 Lymph node: Hodgkin's disease ? 4 A ...

Plasmablastic Lymphoma Adrienne L. Webb, DDS General Practice Residency The Ohio State University College of Dentistry 305 W. 12 th Avenue Columbus, OH 43210 Page 2 Plasmablastic Lymphoma Diffuse large B-cell derived lymphoma EBV-related Non-Hodgkin’s lymphoma Strongly associated with HIV, but has been reported in HIV-negative individuals More commonly seen in adults Poor prognosis with average survival time of six months Page 3 Plasmablastic Lymphoma Predilection for the oral cavity with local invasion and rapid dissemination to extraoral sites Pt had a mediastinal lesion approximately 4.5 x 3.8 cm Distinct affinity for extranodal presentation in the oral cavity Particularly in the gingiva and palatal mucosa Page 4 ...

Malignant Lymphomas • Research Paper | 886 | haematologica/the hematology journal | 2006; 91(7) Gerald G.Wulf Anita Boehnke Bjoern Chapuy Bertram Glass Bernhard Hemmerlein Roland Schroers Malcolm K. Brenner Lorenz Truemper CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells A ggressive non-Hodgkin’s lymphomas (NHL) are susceptible to chemo- and radiotherapy, leading to an initial com- plete remission in the majority of patients, and to long-term disease-free survival in about half of those treated with chemotherapy-based combined modality treatment protocols. 1,2 For B-cell NHL, addition of the chimeric anti- CD20 antibody rituximab to chemotherapy significantly improved disease-free survival, 3 an effect explained by complement fixation (CDC), antibody-dependent cell-mediated ...

Data Review of aplaviroc trials Judith Millard, PhD Group Director ID Medicines Development Center, GSK Page 2 Background information • Aplaviroc development stopped due to evidence of idiosyncratic hepatoxicity • 640 subjects dosed, >350 with multiple doses in phase IIb and III • Review of SAEs, AEs and HIV associated conditions – 3 reports found • Squamous cell carcinoma • Burkitt’s Lymphoma • “Possible Lymphoma ” • None reported as “drug related” Page 3 Squamous Cell Carcinoma • 41 y female randomized to COM+APL (600mg BID) – 01APR05: vaginal discharge with blood – 18APR05: enrolled into the APL trial – 28APR05: invasive epidernoid carcinoma of vagina diagnosed by biopsy – 17MAY05: hospitalized: ...

Primary pancreatic lymphoma . Report of five cases. Arcari A, Anselmi E, Bernuzzi P, Berte R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, Cavanna L. Primary pancreatic lymphoma (PPL) is a very rare disease. We report five cases of PPL (4 men and 1 woman, mean age 65 years) diagnosed and treated at our Institution from 1987 to 1997. None of these patients had evidence of extrapancreatic disease and they were categorized as PPL involving pancreas only (stage IE, 3 patients) or pancreas and peripancreatic lymph nodes (stage IIE, 2 patients). The most common presenting symptoms were abdominal pain and weight loss. Imaging techniques showed a mass of the pancreatic head in all cases. The histological diagnosis (3 diffuse-large cell non-Hodgkin's lymphoma and 2 lymphoplasmacytic lymphoma /immunocytoma) was made by ultrasound-guided fine needle aspiration biopsy and tissue core fine-needle biopsy in ...

190 Renal Lymphoma Case Report International Braz J Urol Vol. 32 (2): 190-192, March - April, 2006 Renal Lymphoma . Atypical Presentation of a Renal Tumor Francualdo Barreto, Marcos F. Dall’Oglio, Miguel Srougi Department of Urology, Federal University of Sao Paulo (UNIFESP), Paulista School of Medicine, Sao Paulo, Brazil ABSTRACT Primary renal lymphoma is a rare lesion that represents less than 1% of the kidney’s lesions. The authors discuss the case of a 67-year-old woman with a renal mass identified 7 years after treatment of a non-Hodgkin’s lymphoma , and analyze clinical and prognostic aspects of renal lymphomas. Radiological findings in this case showed an uncommon presentation of the renal lymphomatous lesion which served as a warning that tumors might appear during follow-up as atypical and uncommon lesions. Key words : kidney neoplasms; nephrectomy; ...

ASH 2005, Andre Goy Mantle Cell Lymphoma Mantle Cell Lymphoma Andre Goy, MD Chief Lymphoma Division The Cancer Center @ HUMC, UMDNJ The Promise of Proteasome Inhibition: Future Directions In Lymphoma and Multiple Myeloma Page 2 ASH 2005, Andre Goy Mantle Cell Lymphoma - Rapidly growing number of new drugs in lymphoma - Molecular characterization of tumors - How this will affect our running of clinical trials Landscape is changing - 6% of NHL, M/F = 3/1 - typically advanced stage - B symptoms < 50% cases - 90% extranodal involvement: BM, liver or GI tract - GI tract: - macro (rare polyposis coli) - micro / random biopsies CD19 / 20 / 22 + CD5+ CD10 - CD23 - FMC7+, HLA-DR++, sIg++, > k ...

lymphoma 1581 Primary CNS Lymphoma Hematology Grand Rounds February 17, 2006 Tom Fong, MD Case Presentation HPI: 61 yo female with h/o HTN presents with new onset seizure, with shaking in both hands, confusion, and post-ictal combativeness. No focal weakness or numbness. In ED, found on brain MRI to have mass lesion in left parietooccipital region. Case Presentation PMH: HTN, asthma, depression PSH: S/p TAH, CCK, appy Meds: Nadolol, advair, zoloft Family Hx: CAD, no malignancies Social Hx: Married, works in factory, former smoker, social EtOH ROS: Otherwise negative Case Presentation Vitals – afebrile, BP 140/80, HR 80 Neuro exam: Cranial nerves intact. Mental status exam with mild memory impairment ...

WINTER 2005 | 06 New Lymphoma Treatments are Saving Lives Story on page 2 96264A_d 12/7/05 9:06 AM Page 1 Page 2 RESEARCH 2 Treatment Advances for Lymphoma Have Reduced Deaths by 70% New state-of-the-art treatment advances for patients with follicular lymphoma , previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients’ initial ther- apies because there may be significant differences in overall survival rates, according to researchers at the James P. Wilmot Cancer Center. Scientists compared outcomes for 960 patients treated with three different regimens and survival rates vary from 91 percent for the newest treatments using monoclonal anti- bodies, to 69 ...

lymphoma 1581 Management of Early Stage Diffuse Large B-Cell Lymphoma Shachar Peles Hematology/Oncology Grand Rounds December 16, 2005 Case Presentation 23 year old AAF Neck and Chest wall pain & swelling 13kg weight loss & Night Sweats PE: Extensive, bulky bilat cervical LAD CT Neck, Chest, Abdomen: No disease below the diaphragm Neck CT Extensive neck adenopathy ( 12 x 3.6cm ) Neck CT Neck CT Left periaortic Left subpectoral Pathology Excisional biopsy: Diffuse Large B-cell Lymphoma large neoplastic lymphoid cells with ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 12 December 2005 Doc.Ref.: EMEA/COMP/4/03 Rev.1 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF tositumomab for the treatment of follicular lymphoma On 14 February 2003, orphan designation (EU/3/03/137) was granted by the European Commission to Amersham plc, U.K., for tositumomab for the treatment of follicular lymphoma . The sponsorship was transferred to GlaxoSmithKline Research & Development Limited, United ...

Lymphoma David M. Vail What is lymphoma ? The lymphomas (malignant lymphoma or lymphosarcoma) are a diverse group of cancers that originate from a type of white blood cell called a lymphocyte . They are one of the most common cancers diagnosed in dogs and cats. This cancer usually arises in lymph tissues such as lymph nodes (lymph glands), spleen, and bone marrow; however, it can arise in almost any tissue in the body including the skin, the brain or spinal cord, bones, heart, or intestines. In the cat, it is most commonly found in the intestinal tract. Lymphoma can occur in any breed. Middle-aged to older dogs and cats are most commonly affected; however, young cats that carry the feline leukemia virus may also develop lymphoma . In most cases, the cause of lymphoma is unknown; however, a weak association with herbicide (weed killers) is known in the dog and the feline leukemia and immunodeficiency ...

QC Form 0450 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7862.pdf Catalog #: 7862 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, analyzed ...

QC Form 0444 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7854.pdf Catalog #: 7854 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, analyzed ...

43(5):546-549,2002 C LINICAL S CIENCES Therapy for Stage I Aggressive Non-Hodgkin’s Lymphoma Hanneke C. Kluin-Nelemans Department of Hematology, Groningen University Hospital, Groningen, the Netherlands AlthoughradiotherapywasconsideredsufficientforstageIandlimitedstageIIaggressivenon-Hodgkin’slymphomain the past, new data from randomized studies have shown that intensified chemotherapy or combined modality therapy (multiagent chemotherapy followed by involved field radiotherapy) can result in complete remission in 75-90% of the cases,with5-yearoverallsurvivalrangingbetween82%and89%.However,notallpatientsbenefitfromthismanage- ment.Patientsabove60yearsofage,withhighlactatedehydrogenaseconcentration,poorperformance,orextranodal disease localized in the testis or central nervous system have a much worse outcome. Therefore, typical extranodal character of this disease (40-57% ...

For immediate release 1 February 2005 05-NIK-47 Dr Stefan Dojcinov using the Nikon telepathology system Electronic image from c.mavroleon@defacto.com Telepathology transforms lymphoma diagnosis in Wales Pathologists can now gain access to an expert second opinion virtually instantaneously Using its newly installed Nikon telepathology system, histopathologists in South Wales can now gain access to an expert second opinion on a suspected lymphoma section from a remotely located colleague virtually instantaneously. This is transforming the way members of the All Wales Lymphoma Panel interact while reviewing cases referred to them and, by reducing the need to travel, allows them to use their valuable time far more effectively. "Nowhere is this speed more important than in the pathological examination of frozen sections where tissue samples are taken from ...

lymphoma 1581 Mantle Cell Lymphoma Current Treatment Strategies Linda Verkruyse MD Patient 59 y/o male 11/2000: Initially diagnosed with NHL (mantle zone lymphoma ?) from cervical LN - Treated with CHOP x 6 with CR 9/2002: Disease recurrence with cervical and axillary LAD – Treated with chemotherapy (?) with PR 8/2004: Disease recurrence with fatigue, wt. loss, B symptoms – Re-biopsy of cervical LN: Mantle Cell Lymphoma : Blastoid Variant – Treated with R-ESHAP x 5 with PR 2/2005: Disease recurrence with cervical LAD Mantle Cell Lymphoma Clinical Features 6% of Non-Hodgkins Lymphomas 3:1 male predominance Median age 65 years Extranodal involvement in 90% (bone marrow, GI) Most patients diagnosed with stage III/IV disease ...

Mayo Clin Proc. • October 2004;79(10):1310-1314 • www.mayo.edu/proceedings 1310 PRIMARY MAMMARY (NON-HODGKIN) LYMPHOMA Primary Mammary (Non-Hodgkin) Lymphoma Presenting as Locally Advanced Breast Cancer CASE REPORT S ANDHYA P RUTHI , MD; V ANIA K. S TAFYLA , MD; S TEPHEN W. P HILLIPS , MD; L UIS F. P ORRATA , MD; AND C AROL A. R EYNOLDS , MD From the Division of General Internal Medicine (S.P.), Department of Radiol- ogy (S.W.P.), Division of Hematology (L.F.P.), and Division of Anatomic Pathol- ogy (C.A.R.), Mayo Clinic College of Medicine, Rochester, Minn; and 251 General Air Force Hospital, Athens, Greece (V.K.S.). Individual reprints of this article are not available. Address correspondence ...

Roczniki Akademii Medycznej w Bia³ymstoku · Vol. 49, 2004 Suppl. 1, Proceedings · Annales Academiae Medicae Bialostocensis 76 Abstract Survivin is a member of the inhibitors from the apoptosis family over-expressed in various human cancers. The aim of the study was to evaluate the expression of survivin in lymph nodes, invaded by non-Hodgkin's lymphomas (nHL) and in lymph nodes reactive hyperplasia. We analysed paraffin sec- tions obtained from 50 patients with nHL and from 13 patients with reactive hyperplasia using, an anti-survivin antibody. There was abundant immunoreactivity cytoplasm in 34/50 (68%) patients with nHL and in only 5/13 (38%) with reactive hyperplasia. Out of the 27 patients with aggressive nHL, 19 (70%) revealed survivin expression in almost all tumour cells. Out of the 23 patients with indolent nHL, 16 (70%) revealed the expression but with lower immunoreactivity score. ...

297 Ann Thorac Cardiovasc Surg Vol. 10, No. 5 (2004) Case Report Introduction Primary tumors of the chest wall are uncommon. The incidence of malignancy in primary tumors of the chest wall is approximately 50%. 1) However, malignant lymphoma arising in the pleura are rare, comprising 2.4% of the primary chest wall tumors, 1) and most pleural lymphomas develop in associa- tion with preceding long-standing pleural disease such as long-standing chronic tuberculous pyotho- rax or artificial pneumothorax for lung tuberculo- sis. 2,3) We report a very rare case of primary malig- nant lymphoma arising in the pleura with no his- tory of persistent pyothorax, and discuss pleural lymphoma based on the literature. Case Report A 72-year-old male who had complained of dyspnea on effort for four months was admitted ...

249 Ann Thorac Cardiovasc Surg Vol. 10, No. 4 (2004) Case Report Introduction Resection of a right atrial tumor is usually performed under total cardiopulmonary bypass (CPB) with snares around the superior vena cava (SVC) and inferior vena cava (IVC). When the tumor obstructs orifices of the vena cavae and protrudes into these, it becomes im- possible to establish total CPB with snares of the vena cavae, and hypothermic circulatory arrest is usually needed to resect the tumor completely. We present here a case in which the huge right atrial malignant lym- phoma was successfully resected using vacuum-as- sisted CPB without establishing total CPB or hypoth- ermic circulatory arrest. Case Report A 53-year-old man was transferred from a community hospital to our hospital following hemodynamic collapse. Echocardiography showed that an abnormal mass occu- ...

lymphoma 1581 ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA October 29, 2004 Case presentation 71 year old male Rapid onset right cervical adenopathy Denies fever, sweats, weight loss, pruritis, skin rash PMH: Gastric ulcer, Trauma to right hand, UE fracture Meds: Ecotrin Habits: non-smoker, no excessive Etoh or illicit drug use SH: Retired maintenance man at Anheuser-Busch, married FH: One brother - A&W, no significant family history Case Presentation- Physical Exam Well appearing, appears younger than stated age Afebrile, VSS, Wt 156 lb Half a dozen left cervical lymph nodes, 1-2cm in size, discrete, soft, rubbery Right posterior cervical lymph nodes 1-2cm in size Right supraclavicular node 2.5 x 2cm Right jugulodigastric node ...